title: Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma.
authors.affiliation: 1] Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA [2] Levine Cancer Institute/Carolinas Healthcare System, Charlotte, NC, USA.
authors.forename: S Z
authors.initials: SZ
authors.lastname: Usmani
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: Q
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: Cancer Research and Biostatistics, Seattle, WA, USA.
authors.forename: K
authors.initials: K
authors.lastname: Stratton
authors.affiliation: Cancer Research and Biostatistics, Seattle, WA, USA.
authors.forename: P
authors.initials: P
authors.lastname: Qu
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: S
authors.initials: S
authors.lastname: Yaccoby
authors.affiliation: Cancer Research and Biostatistics, Seattle, WA, USA.
authors.forename: E
authors.initials: E
authors.lastname: Hansen
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: D
authors.initials: D
authors.lastname: Steward
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: S
authors.initials: S
authors.lastname: Panozzo
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: N
authors.initials: N
authors.lastname: Petty
authors.affiliation: Cancer Research and Biostatistics, Seattle, WA, USA.
authors.forename: A
authors.initials: A
authors.lastname: Hoering
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: S
authors.initials: S
authors.lastname: Waheed
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: F
authors.initials: F
authors.lastname: Van Rhee
authors.affiliation: Cancer Research and Biostatistics, Seattle, WA, USA.
authors.forename: J
authors.initials: J
authors.lastname: Crowley
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: B
authors.initials: B
authors.lastname: Barlogie
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D012008:Recurrence; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; C467566:pomalidomide